People · Operator
Named in public records as an officer, director or promoter · active 2020–2020 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Kinnate Biopharma Inc. | — | Biotechnology | Series C | $172.5M | $3.9B | 2020 |
Mark W. Meltz at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark W. Meltz on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Stephen W. Kaldor | 1 | 3 |
| Keith W. Flaherty | 1 | 1 |
| Jim W. Tananbaum | 1 | 1 |
| Dean W. Mitchell | 1 | 1 |
| Carl W. Gordon | 1 | 1 |
| Laurie W. Smaldone Alsup | 1 | 1 |
| Michael W. Rome | 1 | 1 |
| Nima W. Farzan | 1 | 1 |
| Eric W. Murphy | 1 | 1 |
| Bret W. Zbar | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.